Circulating matrix metalloproteinases and their inhibitors in hypertension.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2012-04-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cca.2011.12.021PMID 22245508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension.

  2011cited by this paper
• Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells

  2011cited by this paper
• Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

  2011cited by this paper
• Doxycycline Dose‐dependently Inhibits MMP‐2‐Mediated Vascular Changes in 2K1C Hypertension

  2011cited by this paper
• Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism*

  2011cited by this paper
• Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.

  2011cited by this paper
• Matrix Metalloproteinase Inhibitors

  2010cited by this paper
• Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension

  2010cited by this paper
• Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.

  2010cited by this paper
• TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.

  2010cited by this paper
• Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix.

  2010cited by this paper
• Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension.

  2010cited by this paper
• Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats.

  2010cited by this paper
• Enhanced Matrix Metalloproteinase Activity in the Spontaneously Hypertensive Rat: VEGFR-2 Cleavage, Endothelial Apoptosis, and Capillary Rarefaction

  2010cited by this paper
• Relations of Biomarkers of Extracellular Matrix Remodeling to Incident Cardiovascular Events and Mortality

  2010cited by this paper
• Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases

  2010cited by this paper
• Extracellular matrix alterations in hypertensive vascular remodeling.

  2010cited by this paper
• Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase‐2 activity and expression in a model of renovascular hypertension

  2010cited by this paper
• Inflammatory markers in essential hypertension: potential clinical implications.

  2010cited by this paper
• Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction.

  2010cited by this paper
• Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study

  2009cited by this paper
• Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.

  2009cited by this paper
• Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.

  2009cited by this paper
• Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community

  2009cited by this paper
• Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions

  2009cited by this paper
• Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.

  2009cited by this paper
• Matrix Metalloproteinases: Discrete Elevations in Essential Hypertension and Hypertensive End-Stage Renal Disease

  2009cited by this paper
• Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis.

  2009cited by this paper
• Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.

  2008cited by this paper
• Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices.

  2008cited by this paper
• Small artery remodelling in hypertension: causes, consequences and therapeutic implications

  2008cited by this paper
• Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.

  2008cited by this paper
• Circulating Matrix Metalloproteinase-9 Is Associated with Cardiovascular Risk Factors in a Middle-Aged Normal Population

  2008cited by this paper
• Mechanisms of arterial remodeling in hypertension: coupled roles of wall shear and intramural stress.

  2008cited by this paper
• Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.

  2008cited by this paper
• Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats.

  2008cited by this paper
• Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation.

  2008cited by this paper
• Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin.

  2008cited by this paper
• Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

  2008cited by this paper
• Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers.

  2008cited by this paper
• Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats.

  2008cited by this paper
• Increased Matrix Metalloproteinase 2 Activity in the Human Internal Mammary Artery Is Associated with Ageing, Hypertension, Diabetes and Kidney Dysfunction

  2008cited by this paper
• Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

  2007cited by this paper
• Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature

  2007cited by this paper
• Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene.

  2007cited by this paper
• ACE inhibitors to block MMP-9 activity: new functions for old inhibitors.

  2007cited by this paper
• Impact of the Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 System on Large Arterial Stiffness in Patients with Essential Hypertension

  2007cited by this paper
• Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches.

  2007cited by this paper
• Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats.

  2007cited by this paper
• Role of Matrix Metalloproteinases in Early Hypertensive Vascular Remodeling

  2007cited by this paper
• Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.

  2007cited by this paper
• Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury.

  2007cited by this paper
• Control of matrix metalloproteinase catalytic activity.

  2007cited by this paper
• Abstract 2595: Small Artery Structure is an Independent Predictor of Cardiovascular Events in Essential Hypertension

  2006cited by this paper
• Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.

  2006cited by this paper
• Structure and function of matrix metalloproteinases and TIMPs.

  2006cited by this paper
• Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease

  2006cited by this paper
• Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events

  2006cited by this paper
• Lercanidipine Reduces Matrix Metalloproteinase-9 Activity in Patients With Hypertension

  2006cited by this paper
• Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases.

  2006cited by this paper
• Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice.

  2005cited by this paper
• Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction.

  2005cited by this paper
• Different Involvement of Extracellular Matrix Components in Small and Large Arteries During Chronic NO Synthase Inhibition

  2005cited by this paper
• Effect of Treatment With Candesartan or Enalapril on Subcutaneous Small Artery Structure in Hypertensive Patients With Noninsulin-Dependent Diabetes Mellitus

  2005cited by this paper
• Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.

  2005cited by this paper
• Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.

  2005cited by this paper
• Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart

  2005cited by this paper
• Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.

  2004cited by this paper
• Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction.

  2004cited by this paper
• Clinical and Biochemical Results of the Metalloproteinase Inhibition with Subantimicrobial Doses of Doxycycline to Prevent Acute Coronary Syndromes (MIDAS) Pilot Trial

  2004cited by this paper
• Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness

  2004cited by this paper
• Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

  2004cited by this paper
• Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.

  2004cited by this paper
• The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension.

  2004cited by this paper
• Pressure-Induced Matrix Metalloproteinase-9 Contributes to Early Hypertensive Remodeling

  2004cited by this paper
• Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.

  2004cited by this paper
• Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment

  2003cited by this paper
• Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-α in cultured human umbilical vein endothelial cells

  2003cited by this paper
• Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction.

  2003cited by this paper
• Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke

  2003cited by this paper
• Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease

  2003cited by this paper
• Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry

  2003cited by this paper
• Circulating matrix metalloproteinase‐2 is elevated in patients with congestive heart failure

  2003cited by this paper
• Structural Basis of the Matrix Metalloproteinases and Their Physiological Inhibitors, the Tissue Inhibitors of Metalloproteinases

  2003cited by this paper
• Regulation of Matrix Metalloproteinase (Matrixin) Genes in Blood Vessels: A Multi-Step Recruitment Model for Pathological Remodelling

  2003cited by this paper
• Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells.

  2003cited by this paper
• Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?

  2002cited by this paper
• Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9.

  2002cited by this paper
• Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9)

  2002cited by this paper
• Matrix metalloproteinases: a tail of a frog that became a prince

  2002cited by this paper
• Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms.

  2002cited by this paper
• Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.

  2001cited by this paper
• Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis

  2001cited by this paper
• Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.

  2000cited by this paper
• Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro.

  2000cited by this paper
• Tissue inhibitors of metalloproteinases: evolution, structure and function.

  2000cited by this paper
• Interleukin-1β and Tumor Necrosis Factor-α Decrease Collagen Synthesis and Increase Matrix Metalloproteinase Activity in Cardiac Fibroblasts In Vitro

  2000cited by this paper
• Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.

  1999cited by this paper
• Matrix Metalloproteinases*

  1999cited by this paper
• Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations.

  1999cited by this paper

• Metalloproteinases (MMPs) in hypertensive disorders: role, function, pharmacology, and potential strategies to mitigate pathophysiological changes

  2025cites this paper
• Interaction between plasma matrix metalloproteinases and arsenic, cadmium, lead, and selenium on chronic kidney disease.

  2025cites this paper
• Using Zymography to Assess Circulating Matrix Metalloproteinase (MMP)-2 and MMP-9 in Clinical Samples.

  2025cites this paper
• Features of The Dynamics of Profibrotic Markers and Regression of Left Ventricular Hypertrophy After Renal Denervation in Patients With Resistant Hypertension and Stenosing Atherosclerosis of the Coronary Arteries.

  2024cites this paper
• Association of matrix metalloproteinases (MMPs) gene polymorphisms with periodontitis: a systematic review

  2024cites this paper
• Plasma Levels of Matrix Metalloproteinases 2 and 9 in Patients with Chronic Chagas Heart Disease and Systemic Arterial Hypertension: Correlation with TGF-Beta Plasma Levels

  2023cites this paper
• Determining the Effect of L-arginine and Physical Activity on the Plasma Levels of Endothelin-1 and Tissue Inhibitor of Metalloproteinase-1 in Postmenopausal Women with Hypertension

  2023cites this paper
• Activity of matrix metalloproteinase type 9 and its relationship with calcification of the thoracic aorta in patients with resistant hypertension: cross-sectional comparative study

  2023cites this paper
• Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology

  2022cites this paper
• Cardiac markers: Role in the pathogenesis of arterial hypertension

  2022cites this paper
• World Journal of Hypertension Role in the

  2022cites this paper
• Mechanisms underlying the effects of caloric restriction on hypertension.

  2022cites this paper
• Leukocyte subtypes, gelatinases, and their tissue inhibitors in a group of subjects with asymptomatic carotid atherosclerosis

  2022cites this paper
• Association of matrix metalloproteinase‐9 and nitric oxide with hypertension in obstructive sleep apnea

  2022cites this paper
• MMPs and TIMPs levels are correlated with anthropometric parameters, blood pressure, and endothelial function in obesity

  2021cites this paper
• MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients

  2021cites this paper
• Effects of physical exercise combined with captopril or losartan on left ventricular hypertrophy of hypertensive rats

  2021cites this paper
• Treatment strategies for isolated systolic hypertension in elderly patients

  2020cites this paper
• Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters.

  2020cites this paper
• Matrix Metalloproteinases and Hypertension-Mediated Organ Damage: Current Insights

  2020cites this paper
• Gene coexpression analysis reveals dose-dependent and type-specific networks responding to ionizing radiation in the aquatic model plant Lemna minor using public data

  2019cites this paper
• Matrix metalloproteinases in nephrotic syndrome; a vital but obscure field of research

  2019cites this paper
• Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study

  2019cites this paper
• The effect of endurance training along with L-arginine supplementation on the levels of MMP-2 and MMP-9 in postmenopausal hypertensive women

  2019cites this paper
• Matrix metalloproteinase gene polymorphisms in chronic periodontitis: a case–control study in the Indian population

  2019cites this paper
• The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects.

  2018cites this paper
• Serum or Plasma Matrix Metalloproteinase (MMP)-9 Levels and Cardiovascular Diseases

  2018cites this paper
• RESISTANT ARTERIAL HYPERTENSION

  2018cites this paper
• Association of MMP‐9 gene polymorphisms with nephrolithiasis patients

  2018cites this paper
• The role of some oxidative stress and inflammatory factors in essential hypertension

  2018cites this paper
• Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies

  2017cites this paper
• Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil.

  2017cites this paper
• Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury

  2017cites this paper
• Abnormal Circulating Levels of Metalloproteinase and Their Inhibitor in Hypertensive Patients.

  2016cites this paper
• Association of Common Variants in MMPs with Periodontitis Risk

  2016cites this paper
• Matrix Metalloproteinase (MMP)-9 Levels in Children on Hemodialysis: Association with MMP-9 C-1562T Gene Polymorphism and Vitamin D Levels

  2016cites this paper
• Changes in activities of circulating MMP-2 and MMP-9 in patients suffering from heart failure in relation to gender, hypertension and treatment: a cross-sectional study.

  2016cites this paper
• Matrix Metalloproteinase 2 as a Potential Mediator of Vascular Smooth Muscle Cell Migration and Chronic Vascular Remodeling in Hypertension

  2016cites this paper
• Increased Circulating Tissue Inhibitor of Metalloproteinase‐2 Is Associated With Resistant Hypertension

  2016cites this paper
• Levels of matrix metalloproteinases differ in plasma and serum – aspects regarding analysis of biological markers in cancer

  2016cites this paper
• Exogenous l-arginine reduces matrix metalloproteinase-2 and -9 activities and oxidative stress in patients with hypertension.

  2016cites this paper
• Mechanisms involved in cardiovascular protection associated with a vegetarian diet.

  2016cites this paper
• Isolated Systolic Hypertension: An Update After SPRINT.

  2016cites this paper
• Reduced levels of potential circulating biomarkers of cardiovascular diseases in apparently healthy vegetarian men.

  2016cites this paper
• Matrix metalloproteinase 2 fused to GFP, expressed in E. coli, successfully tracked MMP-2 distribution in vivo.

  2016cites this paper
• Role Of MMP-2 and MMP-9 in Resistance to Drug Therapy in Patients with Resistant Hypertension

  2015cites this paper
• Matrix metalloproteinases as biomarkers of disease: updates and new insights

  2015cites this paper
• Association of Matrix Metalloproteinase-9 Gene −1562C/T Polymorphism with Essential Hypertension: A Systematic Review and Meta-Analysis Article

  2015cites this paper
• Screening of the Binding of Small Molecules to Proteins by Desorption Electrospray Ionization Mass Spectrometry Combined with Protein Microarray

  2015cites this paper
• MMPs in Cardiovascular Diseases: Emerging Pharmacological Targets

  2014cites this paper
• Application of proteomic technologies to discover and identify biomarkers for periodontal diseases in gingival crevicular fluid: A review

  2014cites this paper
• Efeitos inibitórios de drogas ativadoras da via NO-GMP cíclico sobre a produção estimulada de MMP-9 em células endoteliais

  2014cites this paper
• Inducible nitric oxide synthase as a possible target in hypertension.

  2014cites this paper
• Matrix metalloproteinases and left ventricular function and structure in spinal cord injured subjects.

  2014cites this paper
• Application of quantitative proteomic analysis using tandem mass tags for discovery and identification of novel biomarkers in periodontal disease

  2013cites this paper
• Matrix Metalloproteinases 2 and 9 Are Differentially Expressed in Patients with Indeterminate and Cardiac Clinical Forms of Chagas Disease

  2013cites this paper
• Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage

  2013cites this paper
• Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs genetic polymorphisms and plasma levels in hypertensive disorders of pregnancy

  2013cites this paper
• Synergistic transcriptional regulation of collagenase gene expression in chondrocytes

  2013cites this paper
• Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension.

  2013cites this paper
• Recombinant Human Matrix Metalloproteinase‐2 Impairs Cardiovascular β‐Adrenergic Responses

  2013cites this paper
• Matrix metalloproteinases as drug targets in acute pulmonary embolism.

  2013cites this paper
• Angiotensin-II induced hypertension and renovascular remodelling in tissue inhibitor of metalloproteinase 2 knockout mice

  2013cites this paper
• Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura.

  2013cites this paper
• Oscillometric measurement of brachial artery cross-sectional area and its relationship with cardiovascular risk factors and arterial stiffness in a middle-aged male population

  2013cites this paper
• Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR

  2013cites this paper
• Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations.

  2013cites this paper
• Matrix metalloproteinases as drug targets in preeclampsia.

  2013cites this paper
• Matrix Metalloproteinases: A Target in In-Stent Restenosis?

  2013cites this paper
• identification of novel biomarkers in periodontal disease

  2013cites this paper
• Nitric oxide attenuates matrix metalloproteinase-9 production by endothelial cells independent of cGMP- or NFκB-mediated mechanisms

  2013cites this paper
• Expression of matrix metalloproteinases in patients with bipolar disorder.

  2013cites this paper
• Effects of Matrix Metalloproteinase (MMP)‐2 Polymorphisms on Responsiveness to Antihypertensive Therapy of Women with Hypertensive Disorders of Pregnancy

  2012cites this paper
• Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levels.

  2012cites this paper
• Is Isolated Systolic Hypertension Worse Than Combined Systolic/Diastolic Hypertension?

  2012cites this paper
• Comprehensive Evaluation of the Effects of Enalapril on Matrix Metalloproteinases Levels in Hypertension

  2012cites this paper
• Specific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine.

  2012cites this paper